---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-044798"
form_type: "8-K/A"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T14:33:31.622101+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma terminates land transfer agreement with director Shuling Jiang

## Summary
- Board terminated agreement to acquire land in Taoyuan City, Taiwan from director Shuling Jiang on May 16, 2024.
- Jiang is a director, married to Chief Strategic Officer, and owns ~10% of ABVC common stock.
- Company may reconsider the transaction at a later date; no penalty or financial impact disclosed.
- Original agreement was reported on Feb 8, 2024; termination is effective immediately.

## SEC filing metadata
- accession: 0001213900-24-044798
- form_type: 8-K/A
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024044798/0001213900-24-044798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024044798/ea020639401-8ka_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-044798
- JSON: https://secwatch.observer/filing/0001213900-24-044798.json
- Plain text: https://secwatch.observer/filing/0001213900-24-044798.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into Land Transfer Agreement with Shuling Jiang valued at Not disclosed (effective 2024-02-08).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Shuling Jiang
  - Value: Not disclosed
  - Effective: 2024-02-08
  source text: On February 8, 2024, ABVC BioPharma, Inc. (the “ Company ”) filed the initial Current Report on Form 8-K to disclose that it entered into a definitive agreement with Shuling Jiang (“ Jiang ”), pursuant to which Jiang was going to transfer the ownership of certain land she owns located at Taoyuan City, Taiwan (the “ Land ”) to the Company (the “ Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390024044798/0001213900-24-044798-index.htm
- Material Agreements
  ABVC BIOPHARMA, INC. terminated Land Transfer Agreement with Shuling Jiang valued at Not disclosed (effective 2024-05-16).
  - Action: termination
  - Agreement: asset purchase
  - Counterparty: Shuling Jiang
  - Value: Not disclosed
  - Effective: 2024-05-16
  source text: On May 16, 2024, the Company’s board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not proceed with the transfer of land ownership at this time
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390024044798/0001213900-24-044798-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.